BioLayer assays Prince of Wales
Wednesday, 10 September, 2008
BioLayer Corporation [ASX: BLS] has officially entered into a commercial agreement with the Prince of Wales Medical Research Institute.
The two organisations plan to collaborate on an assay and other diagnostic tools for use in the early detection of neurodegenerative diseases such as Parkinson's.
The companies will share IP to create the new detection tools. Under the agreement, BioLayer has the option to develop existing IP from the Prince of Wales under license.
BioLayer expects to exercise that option early next year.
BioLayer has also filed a patent application for a new approach to protecting assay processes for the early detection of neurodegenerative diseases.
A new approach to treating drug-resistant glioblastoma
A new study has revealed that glioblastoma acquires drug resistance through multiple pathways,...
Researchers identify the first step in allergic reactions
Scientists have identified how the first domino falls after a person encounters an allergen,...
Magnetic therapy helps to protect against cancer
A novel approach to stimulate muscle — by using brief and mild pulsed electromagnetic field...
